Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOS | P01100 | 2/20 | 0.50 |
| ▸ | JUN | P05412 | 2/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 2/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289803 | 0.86 | FOS (0.54) | FOSJUNXDHSLC22A12NR1H4 | |
| SCHEMBL4281903 | 0.84 | ALDH1A1 (0.54) | FOSJUNXDHSLC22A12NR1H4 | |
| SCHEMBL28607405 | 0.84 | PTPN11 (0.51) | FOSJUNXDHSLC22A12NR1H4 | |
| SCHEMBL4277471 | 0.84 | ABCB1 (0.52) | XDHSLC22A12ALDH1A1DHODHTP53 | |
| SCHEMBL8493184 | 0.84 | NR1H4 (0.48) | XDHNR1H4ALDH1A1SIRT2POLB | |
| SCHEMBL8136810 | 0.83 | ALDH1A1 (0.47) | XDHNR1H4ALDH1A1SIRT2KDM4E | |
| SCHEMBL15936185 | 0.83 | ALDH1A1 (0.47) | XDHNR1H4ALDH1A1SIRT2TP53 | |
| SCHEMBL6198908 | 0.81 | ALDH1A1 (0.59) | FOSJUNXDHSLC22A12ALDH1A1 | |
| SCHEMBL2958827 | 0.81 | NR1H4 (0.51) | FOSJUNXDHSLC22A12NR1H4 | |
| SCHEMBL9197144 | 0.79 | TSHR (0.47) | XDHSLC22A12NR1H4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-7314888-B1 | Compounds and medicinal use thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| EP-1127869-A1 | NOVEL COMPOUNDS AND MEDICINAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SP1, AP1G1, AP1M1 | FOS 63/4885JUN 20/4885XDH 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.